AGIO Agios Pharmaceuticals, Inc. Stock Quote

AGIO [NASD]

Index	-	P/E	-	EPS (ttm)	-6.39	Insider Own	0.50%	Shs Outstand	54.56M	Perf Week	2.48%
Market Cap	1.18B	Forward P/E	-	EPS next Y	-6.42	Insider Trans	-0.32%	Shs Float	54.07M	Perf Month	-12.67%
Income	-360.40M	PEG	-	EPS next Q	-1.69	Inst Own	-	Short Float	10.91%	Perf Quarter	-28.50%
Sales	0.80M	P/S	1480.20	EPS this Y	-23.60%	Inst Trans	0.22%	Short Ratio	9.69	Perf Half Y	-44.97%
Book/sh	22.13	P/B	1.01	EPS next Y	-123.60%	ROA	-23.50%	Target Price	38.80	Perf Year	-59.62%
Cash/sh	17.41	P/C	1.28	EPS next 5Y	39.00%	ROE	-26.00%	52W Range	20.20 - 62.15	Perf YTD	-32.07%
Dividend	-	P/FCF	-	EPS past 5Y	-3.10%	ROI	-	52W High	-64.07%	Beta	1.49
Dividend %	-	Quick Ratio	21.20	Sales past 5Y	-	Gross Margin	59.30%	52W Low	10.54%	ATR	1.70
Employees	390	Current Ratio	21.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.69	Volatility	7.16% 7.56%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-32.90%	Profit Margin	-	Rel Volume	1.54	Prev Close	22.14
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 BMO	Payout	-	Avg Volume	608.93K	Price	22.33
Recom	2.40	SMA20	-3.35%	SMA50	-16.70%	SMA200	-38.03%	Volume	936,297	Change	0.86%

Dec-03-21

Initiated

BofA Securities

Buy

$54

Jul-30-21

Downgrade

Goldman

Neutral → Sell

$58 → $39

Jul-01-21

Initiated

Raymond James

Mkt Perform

Jun-10-21

Initiated

H.C. Wainwright

Buy

$88

Mar-01-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$50

Mar-01-21

Downgrade

JP Morgan

Overweight → Neutral

$64 → $54

Feb-26-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Oct-22-20

Upgrade

Barclays

Equal Weight → Overweight

$46

Mar-04-20

Initiated

Barclays

Equal Weight

$50

Nov-26-19

Initiated

Cantor Fitzgerald

Overweight

$64

Sep-23-19

Upgrade

Guggenheim

Neutral → Buy

$55

May-23-19

Resumed

Goldman

Neutral

$55

Feb-15-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

$80

Sep-25-18

Initiated

Leerink Partners

Mkt Perform

May-23-18

Initiated

Citigroup

Buy

$117

Apr-11-18

Reiterated

Credit Suisse

Outperform

$80 → $95

Feb-15-18

Reiterated

SunTrust

Buy

$80 → $101

Feb-15-18

Reiterated

Needham

Buy

$72 → $86

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$78

Aug-10-17

Reiterated

Needham

Buy

$54 → $72

May-17-22 12:13PM	Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff Benzinga
May-16-22 04:15PM	Agios to lay off 50 as it sets its sights on later-stage drugs American City Business Journals
04:15PM	Agios Announces Evolution of Research Organization GlobeNewswire
May-12-22 10:00AM	Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress GlobeNewswire
May-10-22 07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022 GlobeNewswire +6.71%
May-07-22 09:02AM	Does Agios Pharmaceuticals (NASDAQ:AGIO) Have A Healthy Balance Sheet? Simply Wall St.
May-05-22 08:15AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Agios Reports Business Highlights and First Quarter 2022 Financial Results GlobeNewswire
Apr-27-22 02:57PM	Top Small-Cap Stocks for May 2022 Investopedia
Apr-21-22 07:00AM	Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022 GlobeNewswire -5.36%
Apr-14-22 08:34AM	Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency GlobeNewswire -5.36%
Mar-01-22 08:35AM	New Strong Sell Stocks for March 1st Zacks
Feb-28-22 07:00AM	Agios to Participate in March Investor Conferences GlobeNewswire
Feb-24-22 05:49PM	Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil Zacks +5.74%
12:03PM	The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics Zacks
08:55AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	Agios Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-23-22 12:57PM	Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More Zacks
Feb-18-22 10:29AM	Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat Zacks
05:41AM	FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder Benzinga
Feb-17-22 03:41PM	Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency GlobeNewswire -5.18%
03:03PM	Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline Zacks
Feb-10-22 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022 GlobeNewswire
Feb-08-22 01:38PM	S&co Inc Buys Royalty Pharma PLC, Edwards Lifesciences Corp, Procter & Gamble Co, Sells ... GuruFocus.com
Jan-18-22 02:57PM	Top Biotech Stocks for Q1 2022 Investopedia -6.04%
Jan-10-22 01:38PM	Seelaus Asset Management LLC Buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Sells ... GuruFocus.com
07:00AM	Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Companys Strategic Vision in Genetically Defined Diseases GlobeNewswire
Dec-22-21 07:00AM	Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 GlobeNewswire
Dec-21-21 04:27AM	Some Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Estimates Simply Wall St.
Dec-17-21 11:38PM	Goldman Sachs Variable Insurance Trust Growth Opportunities Fund Buys Novavax Inc, Ryan ... GuruFocus.com +8.18%
Dec-14-21 09:17AM	Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden Benzinga
Dec-13-21 06:15PM	Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition GlobeNewswire +7.07%
10:30AM	Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent - and -Thalassemia at 63rd ASH Annual Meeting and Exposition GlobeNewswire
07:00AM	Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition GlobeNewswire
Dec-03-21 11:31AM	Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report? Zacks
Nov-15-21 04:01PM	Agios Appoints Richa Poddar as Chief Commercial Officer GlobeNewswire
Nov-04-21 09:00AM	Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition GlobeNewswire -6.99%
06:30AM	CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases GlobeNewswire
Nov-03-21 02:30PM	Agios Pharmaceuticals, inc (AGIO) Q3 2021 Earnings Call Transcript Motley Fool
01:27PM	Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3 Zacks
08:35AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:11AM	Agios Reports Business Highlights and Third Quarter 2021 Financial Results GlobeNewswire
Oct-29-21 11:38AM	Should I Avoid Agios Pharmaceuticals Inc (AGIO)? Insider Monkey
06:22AM	Breakeven Is Near for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Simply Wall St.
Oct-27-21 03:03PM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-21 04:01PM	Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021 GlobeNewswire
Oct-14-21 06:30AM	Scientist behind Vertex CF drugs launches new startup with Atlas Venture American City Business Journals
Aug-30-21 07:00AM	Agios To Present at September Investor Conferences GlobeNewswire
Aug-24-21 09:00AM	Ex-Peloton Therapeutics CEO launches biotech startup with $60M American City Business Journals
Aug-18-21 10:05AM	Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review Zacks -5.38%
07:37AM	The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga
Aug-17-21 04:01PM	Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jul-31-21 03:13AM	Would Shareholders Who Purchased Agios Pharmaceuticals' (NASDAQ:AGIO) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Jul-30-21 12:10PM	Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress Zacks
Jul-29-21 05:00PM	Agios Pharmaceuticals, inc (AGIO) Q2 2021 Earnings Call Transcript Motley Fool
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	Agios Reports Business Highlights and Second Quarter 2021 Financial Results GlobeNewswire
Jul-22-21 03:03PM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks -7.77%
Jul-19-21 12:16PM	Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Jul-15-21 07:00AM	Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021 GlobeNewswire
Jun-29-21 11:15AM	Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug Zacks
Jun-28-21 07:00AM	Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jun-25-21 03:44PM	Top Stocks for July 2021 Investopedia
Jun-23-21 01:11PM	Top Healthcare Stocks for July 2021 Investopedia
Jun-22-21 11:45AM	Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat Zacks -7.23%
07:00AM	Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency GlobeNewswire
Jun-21-21 11:07AM	Agios Pharma Files US Application For Mitapivat In PK Deficiency Benzinga
07:00AM	Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jun-18-21 09:58AM	Obamacare survives: what it means for the future of health care Yahoo Finance Video
Jun-11-21 03:00AM	Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent - and -Thalassemia at the European Hematology Association Virtual Congress GlobeNewswire
03:00AM	Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress GlobeNewswire
May-12-21 10:00AM	Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress GlobeNewswire
09:32AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Insider Monkey
May-02-21 03:08AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Is About To Turn The Corner Simply Wall St.
Apr-30-21 08:46AM	Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress Zacks
Apr-29-21 06:30PM	Agios Pharmaceuticals Inc (AGIO) Q1 2021 Earnings Call Transcript Motley Fool
09:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Agios Reports Business Highlights and First Quarter 2021 Financial Results GlobeNewswire
05:45AM	Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Apr-22-21 12:33PM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-20-21 11:56AM	Is AGIO Stock A Buy or Sell? Insider Monkey
Apr-15-21 07:00AM	Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021 GlobeNewswire
Apr-01-21 07:00AM	Agios Announces Closing of Oncology Business Sale to Servier GlobeNewswire
Mar-27-21 11:31AM	Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report? Zacks
Mar-25-21 04:01PM	Agios Shareholders Approve Sale of Oncology Business to Servier GlobeNewswire
Mar-18-21 07:00AM	Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease GlobeNewswire -5.88%
Mar-01-21 07:00AM	Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma GlobeNewswire
Feb-27-21 01:04AM	Time To Worry? Analysts Just Downgraded Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Outlook Simply Wall St.
Feb-26-21 10:04AM	Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021 Benzinga -5.67%
09:21AM	Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates Zacks
07:00AM	Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias GlobeNewswire
Feb-25-21 07:00PM	Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Agios Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
06:15AM	Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 07:00AM	Agios to Present at March Investor Conferences GlobeNewswire
Feb-11-21 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021 GlobeNewswire
Feb-04-21 11:54PM	Introducing Agios Pharmaceuticals (NASDAQ:AGIO), A Stock That Climbed 41% In The Last Five Years Simply Wall St.
Jan-27-21 07:35AM	The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga
Jan-26-21 04:01PM	Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused GlobeNewswire
Jan-17-21 10:00AM	Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma GlobeNewswire

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 25	Sale	30.00	108	3,240	2,549	Mar 01 04:54 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 22	Option Exercise	0.00	167	0	2,716	Feb 23 04:09 PM
Schenkein David P	Director	Feb 22	Option Exercise	0.00	2,775	0	117,052	Feb 23 04:09 PM
Burns James William	Chief Legal Officer	Feb 22	Option Exercise	0.00	724	0	15,008	Feb 23 04:10 PM
Poddar Richa	Chief Commercial Officer	Feb 22	Option Exercise	0.00	658	0	5,183	Feb 23 04:11 PM
Gheuens Sarah	Chief Medical Officer	Feb 18	Option Exercise	0.00	3,271	0	8,723	Feb 23 04:12 PM
Poddar Richa	Chief Commercial Officer	Feb 18	Option Exercise	0.00	1,884	0	4,525	Feb 23 04:11 PM
FOUSE JACQUALYN A	Chief Executive Officer	Feb 18	Option Exercise	0.00	12,379	0	78,571	Feb 23 04:10 PM
Biller Jonathan	Chief Financial Officer	Feb 18	Option Exercise	0.00	8,523	0	25,641	Feb 23 04:10 PM
Car Bruce	Chief Scientific Officer	Feb 18	Option Exercise	0.00	6,874	0	18,793	Feb 23 04:11 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 16	Sale	30.81	233	7,179	2,549	Feb 18 04:56 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Option Exercise	0.00	360	0	3,413	Feb 16 05:00 PM
Poddar Richa	Chief Commercial Officer	Feb 14	Option Exercise	0.00	1,738	0	3,231	Feb 16 05:00 PM
Burns James William	Chief Legal Officer	Feb 14	Option Exercise	0.00	6,988	0	16,439	Feb 16 05:01 PM
FOUSE JACQUALYN A	Chief Executive Officer	Feb 14	Option Exercise	0.00	11,334	0	69,697	Feb 16 05:01 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 14	Sale	31.25	504	15,750	2,782	Feb 16 05:00 PM
Biller Jonathan	Chief Financial Officer	Feb 10	Option Exercise	0.00	3,667	0	18,467	Feb 14 04:08 PM
Burns James William	Chief Legal Officer	Feb 10	Option Exercise	0.00	1,833	0	10,094	Feb 14 04:06 PM
Poddar Richa	Chief Commercial Officer	Feb 10	Option Exercise	0.00	2,068	0	2,218	Feb 14 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 10	Option Exercise	0.00	777	0	3,292	Feb 14 04:08 PM
Gheuens Sarah	Chief Medical Officer	Feb 10	Option Exercise	0.00	2,162	0	6,210	Feb 14 04:09 PM
Car Bruce	Chief Scientific Officer	Feb 10	Option Exercise	0.00	3,667	0	12,992	Feb 14 04:07 PM
Car Bruce	Chief Scientific Officer	Jan 06	Option Exercise	0.00	3,437	0	10,530	Jan 10 04:06 PM
Biller Jonathan	Chief Financial Officer	Dec 03	Option Exercise	0.00	5,753	0	16,623	Dec 07 04:18 PM
Gheuens Sarah	Chief Medical Officer	Dec 02	Option Exercise	0.00	834	0	4,296	Dec 07 04:18 PM
Alenson Carman	Principal Accounting Officer	Jun 21	Option Exercise	51.51	1,777	91,533	1,777	Jun 23 05:28 PM
Alenson Carman	Principal Accounting Officer	Jun 21	Sale	61.61	1,777	109,481	0	Jun 23 05:28 PM
Bowden Christopher	Chief Medical Officer	Jun 18	Option Exercise	49.99	48,493	2,423,991	63,980	Jun 22 04:44 PM
Bowden Christopher	Chief Medical Officer	Jun 18	Sale	60.11	48,493	2,914,851	15,487	Jun 22 04:44 PM
Bowden Christopher	Chief Medical Officer	Jun 17	Option Exercise	39.76	2,502	99,480	17,989	Jun 21 04:18 PM
Bowden Christopher	Chief Medical Officer	Jun 17	Sale	60.02	2,502	150,170	15,487	Jun 21 04:18 PM
Bowden Christopher	Chief Medical Officer	Jun 10	Option Exercise	39.76	20,853	829,115	36,340	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 10	Sale	60.06	20,853	1,252,437	15,487	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 09	Option Exercise	39.76	7,149	284,244	22,636	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 09	Sale	60.16	7,149	430,117	15,487	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 08	Option Exercise	39.76	6,675	265,398	22,162	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 08	Sale	60.07	6,675	400,939	15,487	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 07	Option Exercise	39.76	4,268	169,696	19,755	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 07	Sale	60.04	4,268	256,232	15,487	Jun 09 04:06 PM
MARAGANORE JOHN	Director	May 28	Option Exercise	0.00	1,686	0	28,443	Jun 02 04:09 PM
CLARK IAN T	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:09 PM
Schenkein David P	Director	May 28	Option Exercise	0.00	1,686	0	114,277	Jun 02 04:07 PM
Clancy Paul J	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:07 PM
Foster-Cheek Kaye I	Director	May 28	Option Exercise	0.00	1,686	0	7,164	Jun 02 04:08 PM
Scadden David	Director	May 28	Option Exercise	0.00	1,686	0	5,535	Jun 02 04:07 PM
Ho Maykin	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience